623 patents currently held

48 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

2 more records may belong here and await a decision; they are not counted.

The next term ends in Nov 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

166

Ending by 2030

Nov 2026

Next term end

378

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 20442045

notable patents fee due within 90 days all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

PROCESSES FOR THE PREPARATION OF (3S,4R)-3-Ethyl-4-(3H-IMIDAZO[1,2- a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-Trifluoroethyl)PYRROLIDINE-1- CARBOXAMIDE AND SOLID STATE FORMS THEREOF US 10,344,036

Cited by 73 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.

Ends Oct 2036 · Low confidence Also notable

Novel Tricyclic Compounds US 8,962,629

Cited by 124 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.

Ends Jan 2031 · High confidence Also notable

Antibody Formulations and Methods of Making Same US 8,420,081

Cited by 136 later US patents, top 5% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.

Ends Jan 2030 · High confidence

Formerly held, still cited

Notable

Apoptosis Inducing Agents for the Treatment of Cancer and Immune and Autoimmune Diseases US 8,546,399

Cited by 130 later US patents, top 5% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.

now held by Genentech, Inc.

Ends Jun 2031 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

4 fees due Nov 16 to 28, 2026 · next Nov 16
8 fees due Dec 2 to 30, 2026 · next Dec 2
13 fees due Jan 4 to 28, 2027 · next Jan 4
8 fees due Feb 4 to 25, 2027 · next Feb 4
7 fees due Mar 8 to 26, 2027 · next Mar 8
15 fees due Apr 3 to 30, 2027 · next Apr 3
13 fees due May 3 to 24, 2027 · next May 3
9 fees due Jun 1 to 30, 2027 · next Jun 1
7 fees due Jul 5 to 26, 2027 · next Jul 5
14 fees due Aug 2 to 23, 2027 · next Aug 2
6 fees due Sep 8 to 29, 2027 · next Sep 8
11 fees due Oct 5 to 28, 2027 · next Oct 5
7 fees due Nov 3 to 12, 2027 · next Nov 3

Which patents, and when each one lapses · Pro

Recent changes

Nov 6Assignment recorded on US 10,864,249: Chemburkar, Sanjay R. and 4 others to AbbVie Inc. Recorded Nov 6, 2026, executed Feb 1, 2017. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76673, frame 614.
Oct 27Assignment recorded on 1 record: Pliushchev, Marina and 10 others to AbbVie Inc. Recorded Oct 27, 2026, executed Dec 17, 2019. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76526, frame 185.
3 of the patents on this record were granted since Aug 17, 2026
27 terms have ended since Aug 17, 2026

What they patent

The 5 largest of its 378 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Processes for the Preparation of (3S,4R)-3-Ethyl-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-Trifluoroethyl)PYRROLIDINE-1-Carboxamide and Solid State Forms Thereof	45 in force	to Oct 2036
Protein Purification Using Displacement Chromatography	12 in force	to May 2033
Apoptosis Promoters	11 in force	to Dec 2030
Template for a Prescription Medicine Container	8 in force	to May 2034
Fed-Batch Cell Culture Methods Using Non-Animal-Based Hydrolysates	8 in force	to Aug 2030

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 7,504,520	Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Use Thereof In force Term ends Nov 25, 2026 · High confidence	In force	Term ends Nov 25, 2026	High confidence
US 10,323,084	Monoclonal Antibodies Against Amyloid Beta Protein and Uses Thereof held by AbbVie Deutschland GmbH & Co. KG In force Term ends Nov 30, 2026 · Medium confidence	In force	Term ends Nov 30, 2026	Medium confidence
US 10,538,581	Anti-Ab Globulomer 4D10 Antibodies held by AbbVie Deutschland GmbH & Co. KG In force Term ends Nov 30, 2026 · Medium confidence	In force	Term ends Nov 30, 2026	Medium confidence
US 7,763,731	Anti-Viral Compounds In force Term ends Dec 20, 2026 · High confidence	In force	Term ends Dec 20, 2026	High confidence
US 8,338,605	Anti-Viral Compounds In force Term ends Dec 20, 2026 · High confidence	In force	Term ends Dec 20, 2026	High confidence
US 7,767,684	Apoptosis Promoters In force Ends no later than Dec 24, 2026 · Medium confidence	In force	Ends no later than Dec 24, 2026	Medium confidence
US 8,748,108	Biomarkers for Identifying Patient Classes In force Term ends Dec 28, 2026 · High confidence	In force	Term ends Dec 28, 2026	High confidence
US 7,632,946	Naphthyridine-Based Antibacterial Compositions In force Term ends Jan 11, 2027 · High confidence	In force	Term ends Jan 11, 2027	High confidence
US 7,910,595	Anti-Viral Compounds In force Term ends Mar 26, 2027 · High confidence	In force	Term ends Mar 26, 2027	High confidence
US 8,586,746	Amino-Aza-Adamantane Derivatives and Methods of Use In force Term ends Mar 28, 2027 · High confidence	In force	Term ends Mar 28, 2027	High confidence

10 of 623 patents shown.

Pro members see all 623.

Pro members: see all 623 patents

Also on record, not counted in the 623: 48 patents in force now held by others · 723 patents ended · 138 applications pending · 878 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

AbbVie Inc.